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TGF-P-signaling with small molecule FKBP12 antagonists that 
bind myristoylated FKBP12-TGF-P type I receptor fusion proteins 
Brent R Stockwell and Stuart L Schreiber 
Background: Growth arrest in many cell types is triggered by transforming 
growth factor beta (TGF-P), which signals through two TGF-P receptors (type I, 
TGF-PRI: and type II, TGF-PRII). In the signaling pathway, TGF-P binds to the 
extracellular domain of TGF-PRII. which can then transphosphorylate TGF-PRI in 
its glycine/serine (GS)-rich box. Activated TGF-PRI phosphorylates two 
downstream effecters, Smad2 and Smad3, leading to their translocation into 
the nucleus. Cell growth is arrested and plasminogen activator inhibitor 1 
(PAI-1) is upregulated. We investigated the role of the immunophilin FKBP12, 
which can bind to the GS box of TGF-SRI, in TGF-b signaling. 
Results: Overexpression of myristoylated TGF-PRI and TGF-PRII cytoplasmic 
tails caused constitutive nuclear translocation of a green-fluorescent-protein- 
Smad2 construct in COS-1 cells, and constitutive activation of a PAI-1 reporter 
plasmid In mink lung cells. Fusing FKBP12 to TGF-SRI resulted in repression of 
autosignaling that could be alleviated by FK506M or rapamycin (two small 
molecules that can bind to FKBP12). Mutation of the FKBPI 2-binding site in 
the FKBP12-TGF-PRI fusion protein restored constitutive signaling. An acidic 
mutation in the FKBPI 2-TGFPRI protein allowed FKBP12 antagonists to 
activate signaling in the absence of TGF-PRII. Further mutations in the TGF-PRI 
FKBPl2-binding site resulted in TGF-b signaling that was independent of both 
TGF-PRII and FKBP12 antagonists. 
Conclusions: Fusing FKBP12 to TGF-PRI results in a novel receptor that IS 
activated by small molecule FKBP12 antagonists. These results suggest that 
FKBP12 binding to TGF-PRI is inhibitory and that FKBP12 plays a role in 
inhibiting TGF-P superfamily signals. 
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Introduction 
‘I’he transforming growth factor beta (‘I‘GF-p) superfamily 
consists of numerous sccretcd dimeric polppcptides with a 
cystcine-knot fold 1 l-31. ‘I‘his divcrsc sllperfamily includes 
factors rhat regulate sexual development (activins, inhib- 
ins, Miillcrian-inhibiting suhstancc [MIS]). cmbrvonic 
patterning (decapcntaplegic [DPP], nodal, hone morpho- 
genetic proteins [ H.\lPs]. vegetat hcmispherc protein 
[Vg-11. growth and diffcrcntiation factors [GDFs] and 
activin). bone formation (‘I’GF-Ps. IJJIPs) and neuronal 
survival (GI)SF, ncurtllrin and perscphin) 141. TGF-P 
itself is a multifunctional polypeptidc signaling factor that 
can regulate cell proliferation, differentiation, apoptosis 
and expression of cxtracellular matrix proteins, such as 
plasminogen activator inhibitor 1 (P/AI-l) 141. ‘I’wo distinct 
scrine/thrconine kinasc receptors. referred to as type I 
(‘I‘GF-fiRI) and type 11 (‘I’GF-PRII) TGF-P rcccptors. arc 
necessa? and sufficient for transducing most TGF-b- 
induced signals across the plasma membrane of a target 
ccl1 [C61. ‘I‘GF-p initially binds to TGF-SKII and forms a 
complc’c that can srlbscquentl\- recruit ‘TGF-BRl 171. Smad 
proteins constitute 3 novel class of signaling proteins that 
fllnction as downstream cffectors of TGl:-p signaling I)\; 
transmitting the ‘I’C;l~-p signal from the plasma membrane 
to the nucleus of a target cell. Smadl and Smad5 arc down- 
stream of the l3MP receptors [8.9], Smad2 and Smad3 are 
components of the ‘I‘GF-p and activin signaling pathways 
[ 10.11 J and Smadl is a common factor rccluircd for ‘I‘GF-p, 
activin and INI’ signalin:: [12]. In addition, SmadO and 
Smad7 inhibit T(;F-P signaling [13-IS]. I.pon ‘TGF-P 
stimulation. l’(GF-IJRTI phosphor)-laws ‘I’(;F-PRI in the GS 
box, a juxtamembrdnc region of ‘I’GF-PRI rich in glrcinc 
and serine residues. Activated ‘I’GF-PRI phosphor~lates 
Smad2 and Smad.3 [11.16,17), which then associate with 
each other, as well as with Smad4 [ 12,18,19]. Smad2, SmadR 
and Smad4 all subsequentlg translocate from the c\;toplasm 
to the nucleus [ 17.181, where they activate the transcription 
of ‘I’GF-p-responsive genes [ 10,20-121. 
Although the identification of Smad proteins has illumi- 
nated a crucial aspect of TGF-p signaling. the role of acccs- 
soy factors is not full!: Ilnderstood. Three proteins have 
been shown to associate with the TGF-b receptors in ):east 
two-hybrid cxpcriments: the $1 MS fnrnesvltransferasc a 
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Constructs and structures of small molecules 
used in this study. (a) Schematic of fusion 
proteins with llnked immunophillns and TGF-P 
receptor cytoplasmic tails. The following 
abbreviations are used: TGF-P, transforming 
growth factor beta; TGF-PRI, type I TGF-b 
receptor; TGF-BRII, type II TGF-P receptor; M, 
14 amino-acid myristoylation sequence from 
c-Src 1341; F, wild-type 12 kDa FK506- 
binding protein (FKBPI 2); Fpk, GlyES+Pro, 
IleSO-+Lys (PK) double mutant of FKBP12 
1351; A, cyclophilin A; GFP, Ser65-+Thr 
mutant of green fluorescent protein; T,, 
residues 153-501 of rat TGF-@RI (known as 
R4); T,[Dl, ThrPOP+Asp mutant of T,; T,[AA], 
Leul91 -Ala, Pro1 92GAla double mutant of 
T,; T,[AADl, Leul91 +Ala, Pro1 92+Ala, 
ThrPOP+Asp triple mutant of T,; T,[D,KD], 
ThrPOS-tAsp, LysPBO+Arg kinase-dead 
double mutant of T,; T,,. residues 193-567 of 
human TGF-BRII; T,,[KD], Lys277-+Arg 
(K277R) kinase-dead mutant of T,,. 
(b) Structures of the small molecule FKBP12 
antagonists rapamycin and FK506M. 
subunit (T;“l’c~) 12~2.5J and the immunophilin 12K.506- 
binding protcin 12 (FKHP12) interact with TGF-pRI [Xl, 
whereas TGF-P receptor-interacting protein-l (TRIP-l) 
interacts with ‘I’GF-fiRI1 [27]. U ccausc overall protein iso- 
prcnylation levels arc not affected by TGF-P and L744-832, 
an inhibitor of FTa activity, dots not affect ‘IXF-p- 
induced gcnc responses, the enzymatic activity of F’Ta is 
not likely to bc involved in ‘I’GF-p signaling 1241. Thus far. 
the physiological rele\,ancc of ‘I’RIP-1 has not been cstab- 
lished. ‘I’he third potential accessory factor, FKBPIZ, WdS 
shown to associate, in a yeast two-hybrid assay, with the 
cytoplasmic domain of all type I TGF-P superfamily reccp- 
tars tested 1281. It w:as also shown that cell-permeable, small 
molecule ITKBPI 2 antagonists can prevent the association 
of FKHP12 with TGF-PII1 in both yeast two-hybrid 1261 
and coimmunoprccipicacion experiments [28,29]. Several 
reports 12%311 have shown that mutant type I receptors 
chat do not bind FKBPIZ can still transduce some or all of 
‘I’GF-P’s effects, demonstrating that FKBP12 association 
with TGF-PRI is not required for signaling. 
It has been suggested that FKBPlZ negatively regulaccs 
TGF-BRI function [28,30,3 I]. Support for this hypothc- 
sis comes from the findings that FKBP12 is displaced 
from TGF-PKI after stimulation by TGF-P [X31], that 
I;KRPlZ-binding-dcfectivc mutants of I’GF-pR1 show an 
increased tcndenc): co be activated spontaneously in the 
absence of TGF-p [30,31], and that binding of FKBP12 to 
TGI:-fiRI correlates with inhibition of ‘I’GF-p signaling 
1.~1 1. The hypothesis that FKBP12 plays an important role 
in TGF-P signaling remains controvcrrial. however. We 
show that fusing FKRP12 to myistoylatcd forms of the 
type I receptor cytoplasmic tail (Figure 1 a; myristoylation 
is a post-translational modification that adds a fart): acid to 
a protein, which cargcts the protein to the cell mcmbranc) 
results in fusion protcins whose ability to intervene in the 
TGF-p signaling pathway can bc regulated by small mol- 
ecule FKBPI 2 antagonists (Figure lb). The results 
demonstrate that FKBP12 can rcprcss TGF-P type I 
receptor signaling activity in fusion proteins and that irs 
repressive actions can bc prevented by small molecules 
that interfcrc with FKBPlZ-TGF-PRI interactions. 
Results 
Two assays for TGF-fi receptor activation 
\Ve used two assays to determine whether chimcric 
TGF-P receptors had transduced a TGF-P-like signal. 
First, WC used the reporter plasmid p3’1’PI,ux, developed 
by Massague and coworkers [32], which contains a syn- 
thctic TGF-P-responsive promoter chat consists of three 
phorbol-response clcmena and the PAI- promoter/ 
enhancer. ‘I’he plasmid has been used to measure the 
amount of cxtracelllllar matrix protein production induced 
by TGF-p [32]. 
We also monitored the sllbcellular localization of a 
green fluorcsccnt protcin (GFP-Smad2 fusion protein 
(Figure la). Cotransfection of full-length, wild-type 
TGF-PRI and TGF-pKII along with GFP-Smad2 into 
COS-I cells resulted in a cytoplasmic fluorescent signal that 
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Figure 2 
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GFP-Smad2 translocates to the nucleus in 
response to TGF-PI in live COS-1 cells. 
COS-1 cells were transiently transfected with 
GFP-SmadP, wild-type TGF-PRI and wild-type 
TGF-PRII, stained with Hoechst 33256 to 
Identify the nucleus and treated with or without 
200 pM TGF-Pl for one hour. The left column 
shows the GFP signal (FITC filters), the center 
column shows the location of the Hoechst- 
stained nucleus (no filters) and the right column 
shows a phase-contrast image of the same cell. 
The images shown are representative of most 
transfected cells in each experiment. 
Magnification is 1000 X. 
migrated to the nucleus following treatment with 200 13x1 
‘ITiF-pl (Figure 2). As expected, cotransfection of both 
translocation (data not shown). GFP alone did nor migrate 
under any of the conditions tested (data not shown), indi- 
wild-t);pc receptors was required for (;Fl’--Smad2 nuclear eating that .Tma& was rcquircd for nuclear translocation. 
Figure 3 
Myristoylated TGF-P receptor cytoplasmic 
tails signal constltutively. (a) GFP-SmadP 
translocatlon is constitutive when 
myristoylated cyclophilin-A-TGF-PRI and 
cyclophilin-A-TGF-[SRI1 fusion proteins (MAT, 
and MAT,,) are coexpressed, but does not 
occur with a kinase-dead type II receptor 
construct MAT,,[KD]. COS-1 cells were 
transfected with GFP-SmadP. MAT, and 
either kinase-active MAT,, or kinase-dead 
MAT,,[KDl and viewed live under a 
fluorescence microscope. Images were 
obtained as described in Figure 2. 
(b) Myristoylated TGF-P receptor cytoplasmic 
domains activate the PAI- promoter. Mvl Lu 
mink lung epithelial cells were transfected 
with the PAI- -based reporter p3TPLux, MAT, 
and either MAT,, or MAT,,[KD] and treated with 
nothing or 1 FM FK506M. Luciferase activity 
induced from p3TPLux is shown. Error bars 
represent one standard deviation. (c) A model 
for constitutive TGF-13 signaling. 
Overexpressing the cytoplasmic domains of 
the receptors results in constitutive TGF-P 
signaling because of their natural affinity for 
one another. The cyclophilin domains have no 
effect on TGF-P signaling. CypA, 
cyclophilin A; P. phosphate group. 
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Small molecule FKBP12 antagonists mimic 
TGF$ in the presence of two fusion proteins: 
a myristoylated PK mutant of FKBPl2 fused 
to the TGF-PRI cytoplasmic tail and a 
myristoylated TGF-PRII cytoplasmic tail. 
(a) Nuclear translocation of GFP-SmadP in 
response to FK506M or rapamycin. COS-1 
cells were transfected with GFP-SmadP, 
MF,,T,, and either MAT,, or MAT,,[KD], treated 
with the indicated compounds for one hour 
and viewed live under a fluorescence 
microscope. Images were obtained as 
described in Figure 2. (b) FK506M and 
rapamycin activate the PAI- promoter. Mvl Lu 
cells were transfected with the PAI- -based 
reporter p3TPLux, MF,,T, and either MAT,, 
(kinase active) or MAT,,[KDl (kinase dead) and 
treated with nothing (NT), 1 pM FK506M or 
1 FM rapamycin (rap) for 24 h. Cells were 
lysed and luciferase activity was measured. 
(c) Dose-response for GFP-SmadP nuclear 
translocation in response to rapamycin 
treatment in the presence of MFokT, and MAT,,. 
COS-1 cells were transfected as in (a), 
treated with the indicated concentrations of 
rapamycin for one hour and photographed as 
in Figure 2. (d) A model for FKBP12 
antagonist-dependent activation of TGF-P 
signaling. Fusing a PK mutant of FKBP12 to 
TGF-BRI results in inhibition of what would 
otherwise be a constitutive signal (see 
Figure 3a). The association of the PK mutant 
of FKBP12 with the TGF-BRI cytoplasmic 
domain can be disrupted by FKBP12 
antagonists, allowing TGF-P-independent 
signaling to occur. 
Membrane-localized TGF-j3 receptor cytoplasmic tails 
signal constitutively 
When WC cotransfectcd myristoylatcd cyclophilin-i\- 
‘I‘GF-b rcccptor chimeras (MA’I’, and MA’I’,,, Figure la; 
cyclophilin A is an enzyme that, like FKRP12, catalyzes 
the interconversion of cric and h-ms isomers of the 
peptide amide bond at prolyl positions in polypeptides. 
and bccausc cyclophilin does not bind TGF-fiRI, WC 
used this module in place of FKBPl2 as a neutral domain 
that would serve as a control) we found that GFP-Smad2 
was constitutively localized to the nucleus (Figure 3a) 
and p3TPLux was constitutively activated (Figure 3b). 
These results indicate that overexpression of the recep- 
tor cytoplasmic tails at the plasma membrane causes 
autosignaling (Figure 3~). A kinasc-dead mutant of the 
t);pc II receptor (h~lA’l’,,[KI~]. ITigure la) did not signal 
constitutivcly in the presence of MAT, (Figure 3a.b). 
Cytosolic, nonmyristoylated constructs did not signal 
constitutively when coexpressed (data not shown and 
[33]), indicating either that effective concentrations arc 
higher at the mcmbranc or that rcccptor activation 
rcquircs mcmbranc localization. &‘hcn p3’I‘PLux. MI’I’, 
and MA’I’,, wcrc cotransfcctcd into \/Iv1 I,u mink lung 
cells, there \vas some additional reporter gene activation 
induced by an FKRP12 antagonist (Figure 3b), suggest- 
ing that in these cells endogenous FKBPl2 could play a 
role in partially repressing TGF-P-rcccptor-mcdiatcd 
signaling (see the Introduction section). 
A fusion protein consisting of FKBPl2 and the TGF-BRI 
cytoplasmic tail can be activated by FKBPlP antagonists 
FKHP12 associates. in a yeast two-hybrid assay, with the 
cytoplasmic domain of many type I TGF-fi superfamily 
rcccptors [28]. \T!hcn WC cotransfcctcd .\IA’l’,, with a 
m);risto):lated FK131’12-‘l‘(~F-~R1 fusion protcin (MF,,‘I’,, 
Figure la), we observed that the autosignaling dcscribcd 
above ISIS repressed (compare Figure 4a and Figure 3a). 
Two FKRP12 antagonists, rapam);cin and FK.506~1 [34], 
Research Paper TGF-b signaling with FKBPl2 antagonists Stockwell and Schreiber 389 




??Kinase active type II 




NT FK506M Rap 
GFP-SmadP 
__ 
however, activated T(;F-p signaling in the presence of 
MF,,T, and MAT,,. Both rapamycin, which can bind 
FKBP12 and FKBPl Z-rapamycin-associated protein 
(FRAP) simultaneously, and FK506M, a conventional 
FKBP12 antagonist, induced the nuclear accumulation af 
GFP-Smad2 within one hour of treatment (Figure 4a). 
CrFP-Smad2 remained in the cytoplasm when a kinase- 
dead construct (MA’I‘,,[KD], Figure la) was used 
(Figure 4a). Leaving out either receptor from the transfec- 
tion resulted in a cytoplasmic GFP-Smad2 localization that 
could not bc altered using FKBPIZ antagonists (data not 
shown). ‘I’hc EC,, for rapamycin-induced GFP-Smad2 
translocation was approximately 100 nM (Figure 4~). 
We tested whether FKS06M and rapamycin could activate 
the TGF-p-responsive rcportcr p3TI’Lux when MF,,k’l’, 
and MAT,, were cotransfccted into MvlLu mink lung cells. 
Both I;KBP12 antagonists activated the reporter modestly 
when the kinase-active construct MA’I’,, was used but 
neither was able to when the kinasc-dead construct 
MhT,,[KD] was used (Figure 4b). As in the GI;P-Smad2 
translocdtion assay, both type I and II receptor constructs 
were required for this effect (data not shown). 
A Gly89+Pro, IlcOO+Lys (I’K) double mutant of 
FKBP12 (I:,,,.) does not inhibit calcincurin (a phosphatase 
that is involved in T-cc11 activation and is not likely to bc 
involved in the ‘I’GF-b signaling pathway; see the Discus- 
sion section) when hound to l~K.506, in contest to wild- 
type FKRPIZ [X.5]. Also, the only characteristic common 
to FK506M and rapamycin is their ability to bind FK131’12 
potently. These data suggest it is the ability to bind 
FKBPIZ that is responsible for C;I;P-Smad2 nuclear 
translocation and activation of p3TPLux. ‘1%~ finding that 
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LeuPro + AlaAla 
A TGF-BRI cytoplasmic tail mutant 
(Leul91 -tAla, Pro1 92+Ala [AA]) that does 
not bind FKBP12 is constitutively active, even 
when fused to the PK mutant of FKBP12, in 
the presence of a krnase-active TGF-BRII 
cytoplasmic tail. (a) GFP-SmadP 
translocation occurs constitutively when 
MF,,T,[AA] is cotransfected with the kinase- 
active construct MAT,,, but not a kinase-dead 
construct MATJKDI. COS-1 cells were 
transfected with GFP-SmadP and the 
indicated constructs and photographed as in 
Figure 2. (b) The PAI- promoter is activated 
constitutively when MF,,T,[AAJ and MAT,,, but 
not MAT,,[KD], are cotransfected. Mvl Lu cells 
were transfected with p3TPLux and the 
indicated constructs and treated with nothing 
or 1 PM FK506M. (c) A model for Ilgand- 
independent activation of TGF-P signaling 
with FKBPl P-binding-defective TGF-PRI. 
FKBP12 cannot bind the AA mutant of 
TGF-PRI and therefore cannot inhibit the 
constitutive signaling caused by 
overexpression of the cytoplasmic domains of 
the two receptor tails (see Figure 3~). A, 
alanine. 
ClO-acctamido-PK.506, an FK506 derivative dcfectivc in 
FKBD12 binding (D.J. Austin and S.I,.S.. unpublished 
results), does not induce GFP-Smad2 translocation or 
activation of p3TI’l.u~ further supports this conclusion 
(data not shown). 
A TGF-BRI cytoplasmic tail mutant that does not bind 
FKBP12 is constitutively active, even when fused to FKBP12 
FKBP12 binds ‘I’GF-j3RI in yeast two-hybrid [26] and 
coimmunoprecipitation [29,31] assays, and mutation of 
the Icucine-prolix FKHPlZ-binding site in the GS box 
of TGI:-BRI abolishes the interaction in both assays 
[30,31]. We invcstigatcd whether a similar mutation in 
hlF ‘I’ pk , would prevent FK13Pl2 from repressing ‘I’GF- 
PRI. We made Lcul9l+Ala. I’rol92+Ala (L191.4, 
P19’2A) mutations in the GS box of ‘I‘(;F-PRI, generating 
the construct R~lF,,T,[AX] (Figure la). \\:hen this con- 
struct was cotransfcctcd with \l:\T,,, (;FP-Smad2 
translocated to the nucleus constitutively and the I’AI-1 
promoter was activated constituti\x$ (Figure %,I~). ‘I’hcsc 
results indicate that binding of I..KBPlZ is critical for 
repression of ‘IGF-(3Rl signaling activity. ‘I’here was a 
modest cnhancemcnt of reporter gcnc activity following 
addition of FK506h1, likely due to displacement of 
E‘KBP12 from endogcnous ‘ICF-ORI. Furthermore. 
cotransfcction of hlF,,,T,[AA] with the kinasc-dead con- 
struct MA’I‘,,[KI>] did not result in nuclear translocation of 
GFP-Smad2 or activation of p3’l’PLux (Figure .%,b), again 
indicating that the kinasc activity of TGIT-[3RII is rccluired 
for constituti\:e signaling. 
Figure 6 -.- .~ -. .-. .~. ~ 
An acidic mutation on TGF-[%RI allows 
activation of p3TPLux in response to FKBP12 
antagonists in the absence of TGF-PRII. 
(a) DR26 cells were transfected with p3TPLux 
and MF+T,ID] (kinase active), MF,,T,[D,KDl 
(kinase dead) or MF,,T, (kinase active without 
acidic mutation) and treated with nothing (NT), 
1 FM FK506M or 1 pM rapamycin (rap). 
(b) DR26 cells were transfected with p3TPLux 
and MF,,T,[Dl (kinase active) or MF,,T,(D,KDI 
(kinase dead) and treated with the indicated 
concentrations of FK506M. (c) Mutation of the 
FKBPl2-binding site in the context of the 
acidic mutation results in constitutive activation 
of p3TPLux in the absence of TGF-PRII. DR26 
cells were transfected with p3TPLux and 
MFpkT,[D] or MF,,T,[AAD] (FKBPl P-binding 
deflclent) and treated with nothing or 1 PM 
FK506M. Cd) A model for FKBP12 antagonist- 
dependent signaling in the absence of TGF- 
PRII. The acidic (ThrPOP+Asp) mutant of TGF- 
BRI does not signal constitutively because the 
PK mutant of FKBP12 binds intramolecularly to 
the receptor and inhibits signaling. Addition of 
FKBP12 antagonists (or mutation of the 
FKBPl P-binding site) causes activation of 
signaling. D, aspartic acid. 
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FKBPl2 represses and FKBPl2 antagonists derepress a 
TGF-BRII-independent mutant of TGF-PI 
An acidic (Thr204+Asp) mutant of full-length human 
TGF-PRJ is partially active, even in the absence of the 
TGF-I)RJJ [36]. We tested the effect of the corresponding 
Thr202-+Asp mutation in the rat type I receptor tail, in 
the context of the construct MF,,,,‘I’,[D] (Figure la). ‘I‘his 
construct was not constitutivcly active, but was activated 
by the FKBJ’I 2 antagonists FK506M and rapamycin, even 
in the absence of ICF-PI<11 (Fig11re 6d). ‘I’rcating mink 
lung cells transfected with hll;,kT,[l>] and p3TPLux with 
FK506hl or rapamycin resulted in activation of p3TPLux 
(l:igure 6a,b). \ve ensured that cndogenous ‘J’GF-PJtJJ 
was not activating MF,,‘I‘,[ II] by using DIG!6 cells, which 
have a dcfectivc cndogcnous TGF-PRJJ 1371. JTurthcr- 
more, in the absence of TGF-PRJJ, neither the kinasc- 
dead construct MF,,‘J’,[D,KD] nor the wild-type ‘l’hr202 
version of the kinase-active construct was activated by 
I~K506M or rapamycin (Figure 6a,b). 
We were iinable to induce complete GFPSmad2 nuclear 
translocation with MF,,,‘r,[D] alone, or with human ‘TGF- 
!3RI(Thr204+Asp), in the absence of ‘I‘GF-j3RIJ (data not 
shown). W’c did observe partial signaling in some cells 
transfccted with ‘J’GF-PRJ(Thr204+Asp) or MAT,[D], 
but GU’P-Smad2 translocation was incomplete (data not 
shown). In contrast, in the luciferasc reporter gene assay, 
activation of the Thr202--+Asp mutant was independent of 
TGf;-PKIJ, and ITKRP12 was able to repress this mutant. 
‘1’0 confirln that it was the ability of FKBI’12 to bind to 
the cytoplasmic domain of the acidic mutant that was 
rcsponsihlc for the repression effect, we mutated the 
FKBP12-binding site on ‘1’I(‘Thr202+Asp) from Icucinc- 
proline to alanine-alanine, generating the triple mutant, 
h4F,,l,l’l[AAD] (Figure la). This construct constitutivcly 
activated p3TPJ,ux (Figure 6c), although again it did not 
induce complete GFP-Smad2 translocation in COS-1 
cells (data not shown). 
Discussion 
Several reports have shown that ‘I’GFj3RI mutants 
unable to bind FKBPIZ can still transduce ‘I’GF-0 
signals, demonstrating that J:KBP12 association with 
‘JYGF-PRJ is not necessary for signaling (2%311. Some 
reports suggest that FKBP12 is capable of inhibiting 
‘I’GF-P signaling [28,31]. Wang et (I/. [ZS] reported that 
myristoylated wild-type FKRP12 (!UJX) inhibited TGF- 
P-induced activation of p3’1’I’J~ux and inactivation of the 
cyclin A promoter (pCAL, cyclin A is a protein whose 
expression is increased during the DNA synthesis phase 
of the cell cycle; TGF-0 causes a reduced level of tran- 
scription from the cyclin A promoter, an effect that has 
been used as a way of detecting the effect of TGF-p on 
cell-cycle progression [Ml), whereas the myristoylated 
PK mutant of FKRP12 (MF,,,K [N]) inhibited p.3’l’J’J,ux 
activation to a lesser extent and did not inhibit inactiva- 
tion of pChL [28]. Hccause Fpk was less effective at 
inhibiting’I’GF-P responses. and the F,,-I;K506 complex 
is not able to inhibit the phosphatase catcineurin, Wangel 
/I/. [281 concluded that FKBPIZ might bc docking an 
392 Chemistry & Biology 1998, Vol 5 No 7 
inhibitory protein, such as calcincurin, to TGF-PRI, and 
that Fpli could bind ‘I-GF-PRI but could not recruit the 
inhibitory protcin. In contrast, we have found that the PK 
mutant of FKHPI 2 is capable of repressing ‘IYGF-p signal- 
ing, when fused to ‘IGF-pRJ. bJ: binding intramolecularly 
to ‘I’GF-PRJ (Figure 4d). It is likely that F,,, simply has a 
decreased affinity for TGF-pR1 compared to wild-type 
FKLSP12 and therefore is less cffecti\:c at binding and 
repressing ‘I’<;F-PRI activity when forced to do so inter- 
molecularly. By tethering the FKHP12 PK mutant to the 
type I ‘I’GF-p receptor tail. wc appear to have found a 
proper balance between a binding sufficient to repress 
signaling yet weak enough to be derepresscd in rcsponsc 
to small molecule FKHP12 antagonists. Although we 
cannot rule out the possibility that wild-type FKBI’IZ 
and Fpk arc recruiting an inhibitor of ‘I’GIT-/3 signaling to 
‘I‘CGF-SRI, the simplest explanation is that FKBP12 and 
F,,k directly inhibit activation of TGF-PRI by binding 
and occluding the GS box of the rcccptor, an important 
clement in TGF-p signaling 1401. 
X report on FKBI’IZ inhibition of ‘ICF-p signaling by 
Chen et N/. [31) suggested that FKBP12 prcvcnts the 
spontaneous activation of ‘IGF-0 receptors, in the 
absence of ‘ICE‘-P. ?‘(.;I--PRI and ‘TGF-PRlI have an 
intrinsic affinity for each other in the abscncc of TGF-p, 
as cvidenccd by the findings that overexprcssion of either 
full-length ‘IGF-j3RJ and TGI:-PRII or their cytoplasmic 
domains causes constitutive activation of p3Tt’l,ux and 
that the cytoplasmic domains of the receptors interact in 
yeast two-hybrid and coimmunoprccipitation expcri- 
ments 1271. Chcn 6~ ul. 1311 demonstrated that TGF-/3RI 
mutants dcfecti\:e in binding FKBPIZ show an increased 
tendency to be activated spontaneously and that I:KRPlZ 
prevents the ligand-indcpcndcnt transphosphory~ation of 
TGF-PRJ by TGF-PRII. Rccausc, in a companion paper 
published elsewhere [33], we have shown that homod- 
imerization of an activated ‘IYGF-PRI cytoplasmic domain 
containing a ThrZOZ+Asp mutation is sufficient to acti- 
vatc TGF-P signaling [?A], it is possible that I:KBPlZ 
prevents spontaneous autophosphorylation of activated 
TGI.‘-/3RI receptors, and thereby prevents signaling by 
TGF-PRl. FKBPlZ might also prevent the association of 
downstream signaling components, such as Smad2 and 
Smad3, with activated ‘XI:-PRI. 
An important qllcstion involves the natural mechanism by 
which ‘IGF-p induces the rcleasc of l:KBP12 from 
TGF-PRI. It could be that phosphorylation of TGF-PRI 
by TGI;-PRII induces the dissociation of FKRP12, or it 
could be that a TGF-PRI autophosphorylation went 
(either in an intermolecular or intramolecular fashion) is 
responsible for the dissociation. We have demonstrated 
that the l’hr20’2-+Asp activating mutation in ‘I‘GFj3RI 
dots not rcmovc the rcprcssive actions of the ITKBP12 PK 
mutant on ‘I’GF-PRJ. 
A recent report that E14.5 fib&lasts from FKHP12-nuH 
mice show normal ‘ICI;-p-dependent activation of 
p3TPI ,ux concluded that rhe interaction bet\vccn 
FKISP12 and TGF-PRI is not physiologically rcle\:ant 1411. 
The study, however. is not exhaustive in the sense that the 
authors looked dirccrly at only a single ‘lXF-P response in 
a ccl1 type that showed just threefold activation of 
p3’IY’Lux in response to ‘El:-p. X cell lint that responds 
poorly to ‘ICJ:-p might be expected to cxprcss low levels 
of the ‘I’GF-P receptors. According to the model of Chcn d 
nl. 1311, u:hereby FK131’12 prelwts spontanenlls activation 
of TGF-PRJ when the receptors arc expressed at a high 
Icl~el, a dramatic effect on T<;F-p signaling would not be 
expected upon removal of I:KBI’lZ from a cell line that 
expresses low Icl;els of the ‘IGF-p receptors. In addition, 
the results of Shou et/r/. 1411 do not rule out the possibility 
that other isoforms of FKRP12 still bind to and repress 
‘I’GF-PRI, or that compensation mechanisms such as 
receptor downregulation can substitute for FK1~1’12. 
Our original intent was to use FKBPl2 as a binding domain 
for small moleclllc dimcrizers [33]. L!!!c fused F,,, and not 
wild-type FKISP12, to TGF-pRl because. based on the 
results of \t’ang d (I/. 1281 and our own experiments, wc 
knew that .\~lFE, but not YlF,,,E. inhibits TGF-p signaling. 
As \vc ha1.c described. however, we obscwed that when F,,, 
is fused directly to ‘I’(;F-PRI, TGF-PRI-mediated signal- 
ing is repressed and can be dcreprcsscd using PKBI’lZ 
antagonists. l’hlls, we found two strategies for acti\.ating 
‘I’C;F-p signaling with small membrane-pcrmeablc organic 
molecules. One consists of fusing binding domain modules 
to the TGF-P receptor tails and using dimeric small mol- 
cc~~lcs to form home-oligomcric and hctero-oligomcric com- 
plcxes of the receptor tails [33]. The second strategy. 
described in this report, consists of fusing the repressor 
FKRPlZ to the type I TGl;-P receptor and using ITKRP12 
antagonists to dereprcss ‘I’GF-P signaling (Figure 6d). 
Significance 
Transforming growth factor beta (TW-p) arrests cell 
growth in many cell types. Two types of TGF-/3 receptors 
(type I, ‘IGF-j3RI and tqye II, TGF-pRI1) mediate the 
ceII response to TGF-p. TGF-P first binds to TGF-PRII, 
which can then recruit and phosphorylate TGF-PRI at its 
GS box (a region rich in glycinc and scrine residues). 
Activated TGF-PRI then phosphoqlates hvo down- 
stream effecters, Smad2 and Smad3, allowing them to be 
translocated to the nucleus. As a result, cell growth is 
arrested and the plasminogen activator inhibitor (PAI-1) 
is upregulated. We were interested in exploring the role of 
the immunophilin FKS06-binding protein 12 (FKRP12) in 
TGF-0 signaUk& as FKRP12 is able to hind to the GS 
box of TGF-fiRI. 
We have demonstrated that fusing a repressor domain to a 
receptor signaling domain results in a novel receptor that 
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is activated by small molecule antagonists of the repressor. 
Although earlier reports found only a synergy between 
FKBP12 antagonists and TGF-p 128,311, we found that 
the activity of a myristoylated fusion protein containing 
the Gly89+Pro, Ilc9O+L,ys (PK) mutant of FlWP12 and 
the intracellular domain of the TGF-p type I receptor can 
be directly rcgulatcd by FKlW12 antagonists, in the 
absence of TGF-P. Overcxprcssion of type I and type II 
receptor cytoplasmic tails causes constitutive signaling, 
but the PK mutant of FKBP12, when fused to the @pe I 
TGF-p receptor, is capable of repressing the autosignal- 
ing. Roth constitutive and FKBPl2-antagonist-depen- 
dent signaling require the presence of either both TGF-P 
receptors or an acidic mutation in the type I TGF-p 
receptor. The repression by FKBP12 is dependent on its 
binding to a leucinoproline motif in the type I TGF-P 
receptor. These results provide further support of the 
hypothesis that FKHP12 functions as an inhibitor of 
TGF-P superfamily signaling, and they illustrate a novel 
method for controlling TGF-p signaling --one that uses 
simple FKBP12 antagonists rather than small molecule 
‘dimerizers’ [33]. Because FKHP12 binds to other 
receptors, including the activin and IMP type I recep- 
tors, this method of regulating receptor signaling might 
be applicable to these systems as well. 
Materials and methods 
DNA constructions 
All constructs were expressed from the mammalian expression vector 
pBJ5.1 1341. R4, a rat TGF-P type I receptor 1421, was obtained from 
Patricia Donahoe and Tongwen Wang. Human TGF-PRI(Thr204+Asp), 
human TGF-PRII and p3TPLux were obtained from Joan Massague. 
pGEXPTK-A, was generated previously (Karen Liu and S.L.S., unpub- 
lished results). The Ser65-tThr mutant of green fluorescent protein (GFP 
or J), was obtained from the plasmid JCBE 1391. Murine SmadP 
(pcsMadR2) was obtained from Richard Harland [lo]. MAE, was gener- 
ated by ligating the Xhol. .%/I fragment of pGEX2TK4, into Xhol, Sall- 
digested MF,,E,. T, was obtained by PCR amplification of residues 
153-501 of R4 using R4 as template and primers H,8 (5’-GCC ATA 
ACC GCA CTG TCA lTC TCG AGC ACC ACC GCG TGC CA-3’) and 
H,12 (5’-GG AAT GTC TAG AGA AlTC lTA CAT lTr GAT GCC TTC 
CTG TTG G-3’). The PCR product was subcloned into pBS3, a pBlue- 
script II SK-denvative in which the Kpnl site had been destroyed by 
Klenow fill-in and blunt-end ligation, to create pBS3-T,. This and all other 
PCR products were sequenced using dideoxy sequencing on both 
strands to ensure that no unwanted mutations had been introduced. The 
T, fragment was subcloned into MAE,, MF,\, and MF,,3E, with Xhol 
and EcoRl sites, to generate MAT,, MFakT, and MF,,BT,, respectively. The 
T,[D] fragment was generated with an amino-terminal flag tag by overlap 
extension PCR using R4 as template and primers 8286-l (5’-lTA GGT 
ACC CTC GAG GAT TAT AAA GAT GAC GAT GAT AAA CAC CAC 
CGC GTG CCA AAT-3’), 8286-2 (5’-GCT lTC lTG TAG CAC AAT 
GTC CCT TGC AAT TGT TCT lTG AAC AAG C-3’), 8286-3 (5’-GAC 
AlT GTG CTA CAA GAA AGC ATC GGC-3’) and 8286-6 (5’-lTC Cll 
GGG TAC CAA CAA TCT CCA TG-3’) and subcloned Into pBS3-T, to 
generate pBS3-T,[D]. The T,[Dl fragment was subcloned into MF,,E,, 
MF,,E, and MAE, to generate MF,,T,[Dl, MF,,ST,IDI and MAT,[DI, 
respectively. An amino-terminally flag-tagged Leul91 +Ala. Pro1 92+Ala 
double mutant of T, was generated by overlap extension PCR using R4 as 
template and primers 8286-l. 8298-l (5’.GCA All GU Cll TGA ACA 
AGC AGT GCG GCG CCT GAT CCA GAC CCT G-3’), 8298-3 (5’- 
CTG ClT Gil CAA AGA ACA All GC-3’) and 8286-6 and subcloned 
Into pBS3-T, using Kpnl and Xhol. The T,[AAl fragment was subcloned 
into MF,,E, to generate MF,,T,[AA]. An amino-terminally flag-tagged 
Leul91 \Ala, Pro1 92-1Ala Thr202-tAsp triple mutant of T, was gener- 
ated by overlap extension PCR using pBS3-T,[D] as template and primers 
8286-1, 8298-1, 8298-3 and 8286-6. The PCR product was first sub- 
cloned into pBS3-T, and subsequently the T,(AADl fragment was sub- 
cloned into MF,,E, to generate MF,,T,[AADl. T,(D, KDI was generated by 
overlap extension PCR using pBS3-T,[D] as template and primers B286- 
l,B286-4 (5’.Cll CTC TAG AAG AGA ATA TCC TCA CGG CAA C-IT 
Cl-T CTC-3’), 8286-5 (5’-AGG ATA lTC TCT TCT AGA GAA GAA 
CGT TCA TGG-3’) and 8286-6. The PCR product was subcloned into 
pBS3-T, to generate pBS3-T,[D.KDl and the T,[D.KDl fragment was sub- 
cloned into MF,,E,, and MF*BE, with Xhol and EcoRl to generate 
MF,,T,[D!KD] and MF,,ST,[D,KD]. respectively. A general GFP expression 
vector pBJ5.1 -JE, was generated from pBJ5.1 -JCBE,, by replacing the 
Xhol, EcoRl fragment with a new fragment formed by annealing and ligat- 
ing oligos 892-l (5’-TCG AGG GGG All ATA AAG ATG ATG ATG 
ATA AAG TCG ACG GGG CAA CAG-3’) and 892-2 (5’~AAT TCT Gil 
GCC CCG TCG ACT lTA TCA TCA TCA TCT lTA TAA TCC CCC-3’). 
Munne Smad2 was amplified by PCR using pcsMADr2 as template and 
primers 8214-l (5’-llT CTC GTC GAC ATG TCG TCC ATC lTG CCA 
lTC ACT CCG-3’) and 82 14-2 (5’.lTT CTC GAA lTC TTA CGA CAT 
GCT TGA GCA TCG CAC TGA AGG-3’) and subcloned into pBJ5.1- 
JE, using Sal1 and EcoRl to generate pBJ5-JE,Smad2 (referred to as 
GFP-SmadP in the text). TGF-PRII was subcloned into pBluescript IISK- 
(Stratagene) with BamHl to generate PBS-TGF-PRII. Residues 193-567 
(up to the carboxyl terminus) of TGF-BRII were amplified by PCR using 
PBS-TGF-PRII as template and primers B5 (5’CTA CTG CTA CCG 
CGT TAA CCT CGA GCG GCA GCA GAA GCT GAG-3’) and 84 (5’. 
GGT GAG AGG GGC AGC CTC TCT AGA CAT GCC CAG CCT 
GCC CCA TAA GAG CTA GTC GAC Tll GGT AGT Gil TAG GG-3’). 
The Xhol, SalI-digested PCR product was first subcloned into pBlue- 
scriptllSK- to generate PBS-T,, and then subcloned into the SalI site of 
MAE, to generate carboxy-terminally flu epltope-tagged MAT,,. A kinase- 
dead Lys277+Arg mutant of T,, (T,,[KD]) was generated by PCR ampllfl- 
cation using primers 85 and 853-l (5’.lTC ATC GGA TCC TGA CTG 
CCA CTG TCT CAA ACT GC-3’), digestion with Xho I and BamHl and 
subsequent ligation into Xhol, Bglll-digested PBS-T,,. The Xhol, SalI frag- 
ment T,,[KDl was subcloned into MAE,, to generate MAT,,[KDl. 
GFP-Smad2 translocation assay 
COS-1 cells were obtained from Patricia Donahoe and matntalned in Dul- 
becco’s Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum 
(FBS). 2 mM L-glutamine, 100 units/ml penicillin G sodium and 
100 pg/ml streptomycin sulfate. For the GFP-SmadP translocation 
assay, 1.3x lo5 COS-1 cells were seeded on coverslips In eight-well 
dishes. For transfection of each coverslip, 300 ng GFP-Smad2. 850 ng 
type I receptor (e.g. MF,,T,) and 850 ng type II receptor (e.g. MAT,,) were 
mixed with 5.5 pl of 2 mg/ml Lipofectamlne (GibcoBRL) in 1 .O ml phenol 
red free and serum free DMEM (VDMEM), incubated at room tempera- 
turc for 30 minutes and then added to a coversllp that had been washed 
twice with VDMEM. The cells were incubated with the DNA/Lipofecta- 
mine mixture for 4 h at 37°C with 5% CO, and then washed twice with 
VDMEM and incubated 16-20 h In growth medium at 37°C with 5% 
CO,. At the end of this time the cells were washed twice with VDMEM 
and incubated with the desired reagents (e.g., FK506M, rapamycin or 
TGF-P) and 500 ng/ml Hoechst 33258 In 1 ml VDMEM. After 1 h, 20 ul 
of VDMEM reagent solution was placed on a microscope slide and the 
coversllp was inverted onto this droplet. The live cells were viewed 
through a 100 X oil immersion objective on a Leitz Laborlux S 1 OOW Hg 
fluorescence microscope and images were captured with a Hitachi HV- 
Cl 2 CCD camera using Flashpoint FPG ~2.50 software (cl 996 Integral 
Technology, Inc.). Fluorescein filters were used to record GFP images 
and no filter was used for Hoechst 33258 images. Images shown in the 
figures are representative of most cells in a given experiment. Each exper- 
iment was performed multiple times and the results were consistent. 
Luciferase assay 
Mvl Lu mink lung eplthelial cells were obtained from the American Type 
Culture Collection (catalog #CCL64) and DR26 cells were obtained 
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from Joan Massague. Both cell lines were cultured in DMEM with 10% 
FBS, 100 units/ml penicillin G sodium, 100 pg/ml streptomycin sulfate 
and 100 pM each of the amino acids alanine, aspartic acid, glutamine, 
glycine, asparagine, and proline. 3.5 x 1 O5 mink lung cells were seeded 
in each 35 mm well of a six-well dish. After 24 h, cells were transfected 
using DEAE-dextran. For each well, 250ng p3Tfl_ux DNA was mixed 
with 250 ng of each receptor DNA (750 ng total DNA), 6 pl 10 mM 
chlorocfuine, 7.5 ul 10 mglml DEAE-dextran and 600 pl minimal essential 
medium (MEM) supplemented with the nonessential amino acids (NEAA) 
and incubated at room temperature for 10 min. The cells were washed 
twice with MEM and the DNA complexes were added to the cells and 
incubated at 37’C with 5% CO, for 3 h. The cells were then shocked 
with 1 ml of 10% DMSO in PBS for 2 min, washed twice with Hanks 
Balanced Salt Solution (HBSS) and incubated in growth media at 37°C 
with 5% CO,. After 20 h, the cells were washed once and incubated in 
DMEM containing 0.2% FBS and NEAA and the reagent of interest (e.g., 
FK506M, rapamycin or TGF-P) for 25-30 h. Cells were incubated on ice 
for 15 min, washed three times with HBSS and lysed in extraction buffer 
(25 mM glycytgtycine, pH 7.8,15 mM MgSO,, 4 mM EGTA, 1 o/, Triton X, 
1 mM DTT, 1 mM PMSF) by shaking gently at 4°C for 30 min. The lysates 
were centrifuged for 5 min at 10,000 g at 4% and stored on ice. 100 pJ 
of lysate was added to 150 pl of assay mixture (25 mM glycylglycine 
pH 7.8, 15 mM MgSO,, 4 mM EGTA, 15 mM K,HPC, pH 7.8, 1 mM 
DTT, 4 mM ATP) and 1501-11 of luciferin buffer (25 mM glycylglycine 
pH 7.8, 15 mM MgSO,, 4 mM EGTA, 10 mM DlT, 167 pM o-luciferin). 
This mixture was placed in a 500 pl microfuge tube inside a glass scintil- 
lation vial, and luminescence was detected by counting in single photon 
mode (SPM) on a Beckman LS 6500 liquid scintillation counter for 15 s. 
The error bars reported represent plus or minus one standard deviation. 
All experiments were performed multiple times in triplicate. 
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